April 27, 2021: A new randomized controlled trial that includes more Black women is needed to evaluate Tecentriq for Triple Negative Breast Cancer in order to keep FDA approval. The FDA doesn’t do patients any favors by continuing to approve a treatment that isn’t shown to help and may actually harm them.
Read More »